Targets › ADRA2A
80 programs from 76 companies in 201 trials: 74 Phase 4, 55 Phase 2, 38 Phase 3, 34 Phase 1; Other, Psychiatry, Cardiovascular; next expected readout Nov 2026.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. (UniProt, P08913)
Open in Phaseline: the race on ADRA2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharmazz | Centhaquine (LYFAQUIN™) α2B-adrenergic receptor agonist (venous) and α2A-adrenergic receptor agonist (arterial); e | ADRA2B, ADRA2A | Phase 4 | Hypovolemic Shock | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Cooper Norcross Health | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Neonatal Abstinence Syndrome | Dec 2026 |
| Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Brimonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Glaucoma | Dec 2026 |
| Sunnybrook Health Sciences Centre | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Delirium | Dec 2026 |
| Cairo University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Incidence of Post-spinal Hypotension | Dec 2026 |
| Mansoura University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Mansoura University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Daniel Coury | Alpha-2 agonist Stimulates alpha-2 adrenergic receptors in the prefrontal cortex to improve attention and | ADRA2A | Phase 4 | ADHD | Jan 2027 |
| John O'Toole | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Lumbar Spinal Stenosis | Feb 2027 |
| Peking University First Hospital | Intranasal dexmedetomidine-esketamine Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist | ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1 | Phase 4 | Adenotonsillectomy; General Anesthesia | Feb 2027 |
| Region Skane | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Osteo Arthritis of the Knee | Mar 2027 |
| Sohag University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| ARS Pharmaceuticals | Epinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic … | Apr 2027 |
| Icahn School of Medicine at Mount Sinai | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Labor | May 2027 |
| James J. Peters Veterans Affairs Medical Center | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension | Jun 2027 |
| University of California, Davis | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension and Shock | Jun 2027 |
| Tecnoquimicas | Preservative-free dorzolamide-timolol-brimonidine combination Carbonic anhydrase inhibitor (dorzolamide), beta-adrenergic antagonist (timolol), and alph | CA2, ADRB1, ADRA2A | Phase 4 | Primary Open-Angle Glaucoma (POAG) | Jul 2027 |
| University of Sao Paulo General Hospital | clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Cocaine Use Disorder | Jul 2027 |
| Seoul National University Hospital | Phenoxybenzamine Adrenergic receptor alpha antagonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 4 | Pheochromocytoma | Aug 2027 |
| University Hospital Dubrava | clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Inguinal Hernia | Sep 2027 |
| Aarhus University Hospital | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Intracerebral Haemorrhage | Sep 2027 |
| Damanhour Teaching Hospital | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Analgesia | Dec 2027 |
| University of Alberta | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Vasoconstriction | Dec 2027 |
| Columbia University | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Cesarean Delivery | May 2028 |
| Children's Hospital Medical Center, Cincinnati | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Feb 2030 |
| Dalian Municipal Central Hospital | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Nebraska Methodist Health System | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Postpartum Preeclampsia | – |
| Tunis University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Sepsis, Severe | – |
| Dalian Municipal Central Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Hassan II University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Section Complications | – |
| Prairie Eye Center | Simbrinza Alpha-2 adrenergic receptor agonist and carbonic anhydrase inhibitor | ADRA2A, ADRA2B | Phase 4 | Open Angle Glaucoma | – |
| Federal University of São Paulo | Triplenex (triple fixed combination) Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker ( | ADRA2A, ADRB1, ADRB2, PTGFR | Phase 4 | Glaucoma | – |
| NHS Greater Glasgow and Clyde | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Sepsis | Nov 2026 |
| Cairo University | Ketodex NMDA receptor antagonist (ketamine) combined with alpha-2 adrenergic receptor agonist (dex | GRIN1, ADRA2A | Phase 3 | Postoperative Delirium (POD) | Dec 2026 |
| Odense University Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Shock | Dec 2026 |
| Alcon Research | Apraclonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | Ocular Hyperemia | Jan 2027 |
| Wake Forest University Health Sciences | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | PTSD | Mar 2027 |
| Jagiellonian University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Blood Pressure Management | Jun 2027 |
| Hospital do Coracao | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Septic Shock | Aug 2027 |
| Opus Genetics | Phentolamine Ophthalmic Solution 0.75% Non-selective alpha-1 and alpha-2 adrenergic antagonist | ADRA1A, ADRA1B, ADRA1D, ADRA2A | Phase 3 | Vision Loss Night; Insulin Resistance | Aug 2027 |
| University Hospital, Bordeaux | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Stroke, Acute | Aug 2027 |
| Loma Linda University | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Postpartum Complication | Dec 2027 |
| Stanford University | Tizanidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | Chronic Pain | Jan 2028 |
| Acer Therapeutics | Celiprolol (ACER-002) Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist | ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1 | Phase 3 | Vascular Ehlers-Danlos Syndrome | Mar 2029 |
| University of Turin, Italy | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Critical Illness | – |
| Santen SAS | Oxymetazoline (STN1013800) Adrenergic receptor alpha agonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 3 | Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction | – |
| University of Maryland, Baltimore | Lofexidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Opioid Withdrawal | Nov 2026 |
| Washington State University | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Stimulant Use Disorder | Dec 2026 |
| Naveen Poonai | IN Ketodex (D4K2) Dexmedetomidine (alpha-2 adrenergic agonist) + Ketamine (NMDA receptor antagonist) | ADRA2A, GRIN1 | Phase 2 | Fracture | Dec 2026 |
| University of Trieste | mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | RETT Syndrome With Proven MECP2 Mutation | Dec 2026 |
| Teikoku Pharma USA | Dexmedetomidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Agitation | May 2027 |
| University of Aarhus | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Hypotension | Dec 2027 |
| Giuseppe Cullaro, MD | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Acute Kidney Injury | Dec 2027 |
| M.D. Anderson Cancer Center | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Advanced Cancer | Dec 2027 |
| Copenhagen University Hospital, Rigshospitalet | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Emergence Delirium | Jan 2028 |
| Hartford Hospital | Tizanidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Post Operative | Jul 2028 |
| Stanford University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Depression | Oct 2028 |
| Indiana University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Alcohol Use Disorder | Aug 2029 |
| University of California, Irvine | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Glioma of Brain | Dec 2030 |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | BRIMOCHOL PF eye drops Combined alpha-2A adrenergic agonist and muscarinic M3 receptor agonist | ADRA2A, M3 | Phase 2 | Presbyopia | – |
| Universidade Federal do Rio de Janeiro | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Hernia, Umbilical | – |
| Guangzhou Novaken Pharm | Dexmedetomidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Preoperative Sedation; Emergence Delirium; Laceration of Skin; Vaginal Delivery … | – |
| Yale University | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Alcohol Use | – |
| Orygen | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Cannabis Use Disorder | – |
| BioCorRx Pharmaceuticals Inc | Lofexidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Opioid Withdrawal (Disorder) | – |
| Tarian Pharma | TAR-0520 Gel Brimonidine tartrate - selective alpha-2 adrenergic receptor agonist | ADRA2A, ADRA2B, ADRA2C | Phase 2 | EGFR Inhibitor-associated Rash | – |
| Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Xylometazoline nasal drops 0.1% Alpha-1 and alpha-2 adrenergic agonist for vasoconstriction | ADRA1A, ADRA1B, ADRA2A | Phase 2 | Nasal Bleeding | – |
| Kingston Health Sciences Centre | norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Shock | – |
| Geriatric Hospital of Nanjing Medical University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Urolithiasis | Dec 2026 |
| University of Alabama at Birmingham | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension in Pregnancy | Dec 2026 |
| Hospital Universitario La Fe | Opioid-Free Anesthesia (OFA) Multimodal non-opioid protocol: alpha-2 agonist (Dexmedetomidine), sodium channel blocker | ADRA2A, Ion channels, NMDA | Phase 1 | Pain Management | Jul 2027 |
| BioXcel Therapeutics | Dexmedetomidine (BXCL501) Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Schizophrenia | Jul 2027 |
| University of Kansas Medical Center | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Blood Pressure | Aug 2027 |
| Terran Biosciences Australia | TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) Alpha-2A adrenergic receptor antagonist | ADRA2A | Phase 1 | Healthy | Dec 2027 |
| Satish R. Raj | Clonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Tachycardia | Dec 2029 |
| Stephen G. Kaler | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Menkes Disease | Jun 2030 |
| Research Institute of Ophthalmology, Egypt | Dexmedetomidine Hydrochloride Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Patients Undergoing External Dacrocystorhinostomy Operations | – |
| Rutgers, The State University of New Jersey | Guanfacine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Mindfulness | – |
| Brigham and Women's Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension | – |
Cesarean Delivery (4) Delirium (4) Healthy (4) Emergence Delirium (3) Breast Cancer (3) Anesthesia (3) Alcohol Use Disorder (3) Shock (3) Fracture (3) Laceration of Skin (2) Postoperative Pain (2) General Anesthesia (2)
small molecule (71), protein or peptide (3), mixed (1)
Mansoura University (2) Cairo University (2) Stanford University (2) Dalian Municipal Central Hospital (2) University of Kansas Medical Center (1) Guangzhou Novaken Pharm (1) Nebraska Methodist Health System (1) Copenhagen University Hospital, Rigshospitalet (1) Universidade Federal do Rio de Janeiro (1) Seoul National University Hospital (1) Wake Forest University Health Sciences (1) M.D. Anderson Cancer Center (1) Icahn School of Medicine at Mount Sinai (1) Federal University of São Paulo (1) Hospital do Coracao (1) Indiana University (1) Tunis University (1) Research Institute of Ophthalmology, Egypt (1) Santen SAS (1) University of Maryland, Baltimore (1)
ADRA2C (68) ADRA2B (39) ADRA1A (33) ADRB1 (32) ADRB2 (31) HTR2A (5) HTR2C (5) ADRA1B (4) ADRA1D (3) GRIN1 (3) Ion channels (2) PTGFR (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.